Intellia Therapeutics, Inc.
NTLAUS売上高
$68M
百万USD
営業利益
$-441M
百万USD
純利益
$-413M
百万USD
ROE
-61.5%
最新FY
EPS
$-3.81
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $6M | $-46M | - |
| FY2021 | Q2 | $7M | $-69M | - |
| FY2021 | Q3 | $7M | $-72M | - |
| FY2021 | FY | $33M | $-268M | - |
| FY2022 | Q1 | $11M | $-147M | - |
| FY2022 | Q2 | $14M | $-101M | $-1.33 |
| FY2022 | Q3 | $13M | $-113M | $-1.49 |
| FY2022 | FY | $52M | $-474M | $-6.16 |
| FY2023 | Q1 | $13M | $-103M | $-1.17 |
| FY2023 | Q2 | $14M | $-124M | $-1.40 |
| FY2023 | Q3 | $12M | $-122M | $-1.38 |
| FY2023 | FY | $36M | $-481M | $-5.42 |
| FY2024 | Q1 | $29M | $-107M | $-1.12 |
| FY2024 | Q2 | $7M | $-147M | $-1.52 |
| FY2024 | Q3 | $9M | $-136M | $-1.34 |
| FY2024 | FY | $58M | $-519M | $-5.25 |
| FY2025 | Q1 | $17M | $-114M | $-1.10 |
| FY2025 | Q2 | $14M | $-101M | $-0.98 |
| FY2025 | Q3 | $14M | $-101M | $-0.92 |
| FY2025 | FY | $68M | $-413M | $-3.81 |
| FY2026 | Q1 | $15M | $-96M | $-0.81 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $30M | $43M | $58M | $33M | $52M | $36M | $58M | $68M |
| 営業利益 | $-32M | $-70M | $-91M | $-106M | $-137M | $-268M | $-458M | $-515M | $-534M | $-441M |
| 純利益 | $-32M | $-68M | $-85M | $-100M | $-134M | $-268M | $-474M | $-481M | $-519M | $-413M |
| 総資産 | $299M | $376M | $347M | $334M | $676M | $1.3B | $1.5B | $1.3B | $1.2B | $842M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $210M | $301M | $278M | $270M | $527M | $1.0B | $1.2B | $1.1B | $872M | $671M |
| 営業CF | - | - | $-61M | $-103M | $-50M | $-225M | $-333M | $-394M | $-349M | $-395M |
| EPS | - | - | - | - | - | - | $-6.16 | $-5.42 | $-5.25 | $-3.81 |
| BPS | $5.83 | $7.09 | $6.15 | $5.34 | $7.78 | $13.93 | $14.04 | $10.93 | $8.42 | $5.68 |
| ROE | -15.1% | -22.5% | -30.7% | -36.9% | -25.5% | -25.8% | -38.4% | -45.8% | -59.5% | -61.5% |